U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C46H56N4O10.H2O4S
Molecular Weight 923.039
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VINCRISTINE SULFATE

SMILES

CC[C@@]1(C[C@@]2([H])C[C@](c3cc4c(cc3OC)N(C=O)[C@]5([H])[C@@]64CCN7CC=C[C@](CC)([C@@]67[H])[C@]([H])([C@@]5(C(=O)OC)O)OC(=O)C)(c8c(CCN(C2)C1)c9ccccc9[nH]8)C(=O)OC)O.OS(=O)(=O)O

InChI

InChIKey=AQTQHPDCURKLKT-PNYVAJAMSA-N
InChI=1S/C46H56N4O10.H2O4S/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6;1-5(2,3)4/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3;(H2,1,2,3,4)/t28-,37-,38+,39+,42-,43+,44+,45-,46-;/m0./s1

HIDE SMILES / InChI

Molecular Formula C46H56N4O10
Molecular Weight 824.9594
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 9
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula H2O4S
Molecular Weight 98.0796
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/pro/vincristine.html

Vincristine is a vinca alkaloid antineoplastic agent used as a treatment for various cancers including breast cancer, Hodgkin's disease, Kaposi's sarcoma, and testicular cancer. The vinca alkaloids are structurally similar compounds comprised of 2 multiringed units, vindoline and catharanthine. The vinca alkaloids have become clinically useful since the discovery of their antitumour properties in 1959. Initially, extracts of the periwinkle plant (Catharanthus roseus) were investigated because of putative hypoglycemic properties, but were noted to cause marrow suppression in rats and antileukemic effects in vitro. Vincristine binds to the microtubular proteins of the mitotic spindle, leading to crystallization of the microtubule and mitotic arrest or cell death. Vincristine has some immunosuppressant effect. The vinca alkaloids are considered to be cell cycle phase-specific. The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.Vincristine was marketed under the brand name Oncovin, but was discontinued. In 2012 the FDA approved a Liposomal formulation of Vincristine, named MARQIBO KIT.

Originator

Curator's Comment:: # Dr. James. Armstrong of Eli Lilly and Company

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P07437
Gene ID: 203068.0
Gene Symbol: TUBB
Target Organism: Homo sapiens (Human)
1.6 µM [IC50]
0.17 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Marqibo

Approved Use

Marqibo® is indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.

Launch Date

1.34438401E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1220 ng/mL
2.25 mg/m² steady-state, intravenous
dose: 2.25 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
VINCRISTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
14566 ng × h/mL
2.25 mg/m² steady-state, intravenous
dose: 2.25 mg/m²
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
VINCRISTINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
25%
VINCRISTINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2.25 mg/m2 1 times / week multiple, intravenous
MTD
Dose: 2.25 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2.25 mg/m2, 1 times / week
Co-administed with::
dexamethasone, i.v.(40 mg)
Sources: Page: p.1,6
unhealthy, 19-62
n = 18
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 19-62
Sex: M+F
Population Size: 18
Sources: Page: p.1,6
2.4 mg/m2 1 times / week multiple, intravenous
Studied dose
Dose: 2.4 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2.4 mg/m2, 1 times / week
Co-administed with::
dexamethasone, i.v.(40 mg)
Sources: Page: p.1,6
unhealthy, 19-62
n = 7
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 19-62
Sex: M+F
Population Size: 7
Sources: Page: p.1,6
DLT: Motor polyneuropathy, Seizure...
Dose limiting toxicities:
Motor polyneuropathy (grade 3, 14.3%)
Seizure (grade 4, 14.3%)
Hepatotoxicity (grade 4, 14.3%)
Sources: Page: p.1,6
2.8 mg/m2 3 times / week multiple, intravenous
Highest studied dose
Dose: 2.8 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 2.8 mg/m2, 3 times / week
Sources: Page: p.701
unhealthy, 32-83
n = 3
Health Status: unhealthy
Condition: Cancer
Age Group: 32-83
Sex: M+F
Population Size: 3
Sources: Page: p.701
DLT: Neutropenia, Thrombocytopenia...
Dose limiting toxicities:
Neutropenia (grade 4, 33.3%)
Thrombocytopenia (grade 4, 33.3%)
Obstipation
Myalgia (grade 3, 33.3%)
Sources: Page: p.701
2.4 mg/m2 3 times / week multiple, intravenous
MTD
Dose: 2.4 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 2.4 mg/m2, 3 times / week
Sources: Page: p.704
unhealthy, 32-83
n = 6
Health Status: unhealthy
Condition: Cancer
Age Group: 32-83
Sex: M+F
Population Size: 6
Sources: Page: p.704
2.25 mg/m2 1 times / week multiple, intravenous
Recommended
Dose: 2.25 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2.25 mg/m2, 1 times / week
Sources: Page: p.8
unhealthy
n = 83
Health Status: unhealthy
Condition: Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL)
Population Size: 83
Sources: Page: p.8
Disc. AE: Peripheral neuropathy, Tumor lysis syndrome...
AEs leading to
discontinuation/dose reduction:
Peripheral neuropathy (10%)
Tumor lysis syndrome (2%)
Sources: Page: p.8
AEs

AEs

AESignificanceDosePopulation
Motor polyneuropathy grade 3, 14.3%
DLT
2.4 mg/m2 1 times / week multiple, intravenous
Studied dose
Dose: 2.4 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2.4 mg/m2, 1 times / week
Co-administed with::
dexamethasone, i.v.(40 mg)
Sources: Page: p.1,6
unhealthy, 19-62
n = 7
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 19-62
Sex: M+F
Population Size: 7
Sources: Page: p.1,6
Hepatotoxicity grade 4, 14.3%
DLT
2.4 mg/m2 1 times / week multiple, intravenous
Studied dose
Dose: 2.4 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2.4 mg/m2, 1 times / week
Co-administed with::
dexamethasone, i.v.(40 mg)
Sources: Page: p.1,6
unhealthy, 19-62
n = 7
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 19-62
Sex: M+F
Population Size: 7
Sources: Page: p.1,6
Seizure grade 4, 14.3%
DLT
2.4 mg/m2 1 times / week multiple, intravenous
Studied dose
Dose: 2.4 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2.4 mg/m2, 1 times / week
Co-administed with::
dexamethasone, i.v.(40 mg)
Sources: Page: p.1,6
unhealthy, 19-62
n = 7
Health Status: unhealthy
Condition: Acute lymphoblastic leukemia
Age Group: 19-62
Sex: M+F
Population Size: 7
Sources: Page: p.1,6
Obstipation DLT
2.8 mg/m2 3 times / week multiple, intravenous
Highest studied dose
Dose: 2.8 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 2.8 mg/m2, 3 times / week
Sources: Page: p.701
unhealthy, 32-83
n = 3
Health Status: unhealthy
Condition: Cancer
Age Group: 32-83
Sex: M+F
Population Size: 3
Sources: Page: p.701
Myalgia grade 3, 33.3%
DLT
2.8 mg/m2 3 times / week multiple, intravenous
Highest studied dose
Dose: 2.8 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 2.8 mg/m2, 3 times / week
Sources: Page: p.701
unhealthy, 32-83
n = 3
Health Status: unhealthy
Condition: Cancer
Age Group: 32-83
Sex: M+F
Population Size: 3
Sources: Page: p.701
Neutropenia grade 4, 33.3%
DLT
2.8 mg/m2 3 times / week multiple, intravenous
Highest studied dose
Dose: 2.8 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 2.8 mg/m2, 3 times / week
Sources: Page: p.701
unhealthy, 32-83
n = 3
Health Status: unhealthy
Condition: Cancer
Age Group: 32-83
Sex: M+F
Population Size: 3
Sources: Page: p.701
Thrombocytopenia grade 4, 33.3%
DLT
2.8 mg/m2 3 times / week multiple, intravenous
Highest studied dose
Dose: 2.8 mg/m2, 3 times / week
Route: intravenous
Route: multiple
Dose: 2.8 mg/m2, 3 times / week
Sources: Page: p.701
unhealthy, 32-83
n = 3
Health Status: unhealthy
Condition: Cancer
Age Group: 32-83
Sex: M+F
Population Size: 3
Sources: Page: p.701
Peripheral neuropathy 10%
Disc. AE
2.25 mg/m2 1 times / week multiple, intravenous
Recommended
Dose: 2.25 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2.25 mg/m2, 1 times / week
Sources: Page: p.8
unhealthy
n = 83
Health Status: unhealthy
Condition: Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL)
Population Size: 83
Sources: Page: p.8
Tumor lysis syndrome 2%
Disc. AE
2.25 mg/m2 1 times / week multiple, intravenous
Recommended
Dose: 2.25 mg/m2, 1 times / week
Route: intravenous
Route: multiple
Dose: 2.25 mg/m2, 1 times / week
Sources: Page: p.8
unhealthy
n = 83
Health Status: unhealthy
Condition: Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL)
Population Size: 83
Sources: Page: p.8
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
likely
yes
yes
yes (co-administration study)
Comment: the total area under the plasma concentration-time curve was 43% smaller in patients who were receiving carbamazepine or phenytoin than in the control group; the concomitant use of strong CYP3A inhibitors should be avoided (e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin). Similarly, the concomitant use of strong CYP3A inducers should be avoided (e.g., dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. John’s Wort)
Page: 31.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Vincristine-induced myocardial infarction.
1975 Dec
Vincristine-induced autonomic neuropathy.
1975 Jul 26
Animal models for the comparative assessment of neurotoxicity following repeated administration of vinca alkaloids.
1979 Jan
Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors.
1992 Feb
Vincristine neurotoxicity.
1992 Mar
Mild axonal neuropathy of children during treatment for acute lymphoblastic leukaemia.
2000
The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance.
2000 Aug
Bilateral transient hearing loss associated with vincristine therapy: case report.
2000 Dec
[Syndrome of inappropriate secretion of antidiuretic hormone in a patient with myeloid antigen positive acute lymphoblastic leukemia after systemic chemotherapy including vincristine].
2000 Jan
Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein.
2000 Jan
Differential sensitivities of MRP1-overexpressing lung tumor cells to cytotoxic metals.
2000 Jan 3
Acute deterioration of Charcot-Marie-Tooth disease IA (CMT IA) following 2 mg of vincristine chemotherapy.
2000 Jun
Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
2000 Mar
Cortical laminar necrosis caused by immunosuppressive therapy and chemotherapy.
2000 Mar
[Severe hemolysis and SIADH-like symptoms induced by vincristine in an ALL patient with liver cirrhosis].
2000 Nov
Venoocclusive liver disease (VOD) as a complication of Wilms' tumour management in the series of consecutive 206 patients.
2000 Oct
Treatment for primary CNS lymphoma: the next step.
2000 Sep
Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat.
2000 Sep 4
Hemolytic uremic syndrome secondary to the treatment of acute lymphoblastic leukemia.
2000 Sep-Oct
Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856.
2001
[An experimental study on the blood vessel sclerosing therapeutic agents for cavernous hemangiomas].
2001 Aug
Down-regulation of catalase gene expression in the doxorubicin-resistant AML subline AML-2/DX100.
2001 Feb 16
Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia.
2001 Mar
Mutation of a single conserved tryptophan in multidrug resistance protein 1 (MRP1/ABCC1) results in loss of drug resistance and selective loss of organic anion transport.
2001 May 11
Inhibition of drug-induced Fas ligand transcription and apoptosis by Bcl-XL.
2001 Sep
Hyponatremia and syndrome of inappropriate anti-diuretic hormone reported with the use of Vincristine: an over-representation of Asians?
2002 Apr-May
A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
2002 Aug
Reversible vincristine-related flaccid paralysis in a child with acute lymphoblastic leukemia.
2002 Aug
Treatment results of aggressive B non-Hodgkin's lymphoma in advanced age considering comorbidity.
2002 Dec
Functional analysis of MRP1 cloned from bovine.
2002 Jun 19
Improvement of combination chemotherapy tolerance by introduction of polycistronic retroviral vector drug resistance genes MGMT and MDR1 into human umbilical cord blood CD34+ cells.
2002 Mar
Primary cardiac lymphoma--a case report.
2002 Mar-Apr
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
2002 May 1
Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma.
2002 Oct
Gliomatosis cerebri: molecular pathology and clinical course.
2002 Oct
Altered temporal pattern of evoked afferent activity in a rat model of vincristine-induced painful peripheral neuropathy.
2003
Enteropathy-associated T-cell lymphoma of the jejunum complicated with intestinal perforation.
2003 Apr
[Clinical analysis of 75 patients with nasopharyngeal non-Hodgkin's lymphoma].
2003 Apr
[Anaphylaxia induced by etoposide--a case report].
2003 Aug
Henoch-Schönlein IgA glomerulonephritis complicating myeloma kidneys: case report.
2003 Aug
Evidence for an antihyperalgesic effect of venlafaxine in vincristine-induced neuropathy in rat.
2003 Aug 1
Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
2003 Jul 15
Bilateral hearing loss during vincristine therapy: a case report.
2003 Jun
Cloning and functional characterization of the multidrug resistance-associated protein (MRP1/ABCC1) from the cynomolgus monkey.
2003 Mar
Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia.
2003 May
Leiomyosarcoma of urinary bladder following cyclophosphamide therapy: report of two cases.
2003 May
Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1).
2003 May 13
The egr-1 gene is induced by DNA-damaging agents and non-genotoxic drugs in both normal and neoplastic human cells.
2003 May 16
Charcot-Marie-Tooth disease and vincristine.
2003 May-Jun
Functional expression of the multidrug resistance protein 1 in microglia.
2003 Oct
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: For Intravenous Use Only. Fatal if Given by Other Routes.
Marqibo is liposome-encapsulated vincristine. 2.25 mg/m2 intravenously over 1 hour once every 7 days.
Route of Administration: Intravenous
In Vitro Use Guide
Treatment of macrophage monolayers for 24 h with vincristine (10(-5)-10(-7) M) inhibited the antibody dependent cellular cytotoxicity (ADCC) by PMA stimulated rat macrophages.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:52:16 UTC 2021
Edited
by admin
on Fri Jun 25 20:52:16 UTC 2021
Record UNII
T5IRO3534A
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
VINCRISTINE SULFATE
EP   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD   WHO-IP  
USAN  
Official Name English
VINCRISTINE SULFATE [IARC]
Common Name English
VINCRISTINI SULFAS [WHO-IP LATIN]
Common Name English
VINCRISUL
Common Name English
22-OXOVINCALEUKOBLASTINE SULFATE (1:1) (SALT) [WHO-IP]
Common Name English
VINCRISTINE SULFATE [MART.]
Common Name English
37231
Code English
LEUROCRISTINE SULFATE (1:1) (SALT)
Common Name English
NSC-67574
Code English
VINCRISTINE SULFATE [USAN]
Common Name English
VINCRISTINE SULFATE [EP MONOGRAPH]
Common Name English
VINCRISTINE SULFATE [USP-RS]
Common Name English
KYOCRISTINE
Common Name English
VINCRISTINE SULFATE [WHO-DD]
Common Name English
VINCALEUKOBLASTINE, 22-OXO-, SULFATE (1:1) (SALT)
Common Name English
VINCRISTINE SULFATE [VANDF]
Common Name English
ONCOVIN
Brand Name English
VINCRISTINE SULFATE [WHO-IP]
Common Name English
VINCREX
Brand Name English
VINCRISTINE SULFATE [MI]
Common Name English
VINCRISTINE SULPHATE
Common Name English
NOVOPHARM
Common Name English
LILLY-37231
Code English
VINCRISTINE SULFATE [USP MONOGRAPH]
Common Name English
VINCRISTINE SULFATE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 259108
Created by admin on Fri Jun 25 20:52:16 UTC 2021 , Edited by admin on Fri Jun 25 20:52:16 UTC 2021
EU-Orphan Drug EU/3/08/555
Created by admin on Fri Jun 25 20:52:16 UTC 2021 , Edited by admin on Fri Jun 25 20:52:16 UTC 2021
NCI_THESAURUS C932
Created by admin on Fri Jun 25 20:52:16 UTC 2021 , Edited by admin on Fri Jun 25 20:52:16 UTC 2021
NCI_THESAURUS C67422
Created by admin on Fri Jun 25 20:52:16 UTC 2021 , Edited by admin on Fri Jun 25 20:52:16 UTC 2021
Code System Code Type Description
MERCK INDEX
M11453
Created by admin on Fri Jun 25 20:52:16 UTC 2021 , Edited by admin on Fri Jun 25 20:52:16 UTC 2021
PRIMARY Merck Index
EPA CompTox
2068-78-2
Created by admin on Fri Jun 25 20:52:16 UTC 2021 , Edited by admin on Fri Jun 25 20:52:16 UTC 2021
PRIMARY
PUBCHEM
5388992
Created by admin on Fri Jun 25 20:52:16 UTC 2021 , Edited by admin on Fri Jun 25 20:52:16 UTC 2021
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
VINCRISTINE SULFATE
Created by admin on Fri Jun 25 20:52:16 UTC 2021 , Edited by admin on Fri Jun 25 20:52:16 UTC 2021
PRIMARY Description: A white to slightly yellow, amorphous or crystalline powder; odourless. Solubility: Freely soluble in water; slightly soluble in ethanol (~750 g/l) TS; practically insoluble in ether R. Category: Cytotoxic drug. Storage: Vincristine sulfate should be kept in a tightly closed container, protected from light, and stored at a temperature between 2 and 8?C. Additional information: Vincristine sulfate is hygroscopic and very toxic. CAUTION: Vincristine sulfate must be handled with care, avoiding contact with the skin and inhalation of airborne particles. Definition: Vincristine sulfate contains not less than 95.0% and not more than 105.0% of C46H56N4O10,H2SO4, calculated with reference to the dried substance.
DRUG BANK
DBSALT000314
Created by admin on Fri Jun 25 20:52:16 UTC 2021 , Edited by admin on Fri Jun 25 20:52:16 UTC 2021
PRIMARY
NCI_THESAURUS
C1739
Created by admin on Fri Jun 25 20:52:16 UTC 2021 , Edited by admin on Fri Jun 25 20:52:16 UTC 2021
PRIMARY
USP_CATALOG
1714007
Created by admin on Fri Jun 25 20:52:16 UTC 2021 , Edited by admin on Fri Jun 25 20:52:16 UTC 2021
PRIMARY USP-RS
EVMPD
SUB05101MIG
Created by admin on Fri Jun 25 20:52:16 UTC 2021 , Edited by admin on Fri Jun 25 20:52:16 UTC 2021
PRIMARY
CAS
2068-78-2
Created by admin on Fri Jun 25 20:52:16 UTC 2021 , Edited by admin on Fri Jun 25 20:52:16 UTC 2021
PRIMARY
FDA UNII
T5IRO3534A
Created by admin on Fri Jun 25 20:52:16 UTC 2021 , Edited by admin on Fri Jun 25 20:52:16 UTC 2021
PRIMARY
HSDB
2068-78-2
Created by admin on Fri Jun 25 20:52:16 UTC 2021 , Edited by admin on Fri Jun 25 20:52:16 UTC 2021
PRIMARY
ChEMBL
CHEMBL90555
Created by admin on Fri Jun 25 20:52:16 UTC 2021 , Edited by admin on Fri Jun 25 20:52:16 UTC 2021
PRIMARY
RXCUI
11203
Created by admin on Fri Jun 25 20:52:16 UTC 2021 , Edited by admin on Fri Jun 25 20:52:16 UTC 2021
PRIMARY
ECHA (EC/EINECS)
218-190-0
Created by admin on Fri Jun 25 20:52:16 UTC 2021 , Edited by admin on Fri Jun 25 20:52:16 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
SUB_CONCEPT->SUBSTANCE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY